Nordic Pharmaceutical Forum
Insider Insights

Nordic Pharmaceutical Forum develops new website to provide ongoing updates on NFL activities


The Nordic Pharmaceutical Forum (NLF) who recently published a new joint Nordic strategy for pharmaceuticals through till 2025, has developed a dedicated website to provide ongoing updates on NLF activities.

The NLF was developed in 2015 as a collaboration to enact strategy focused on innovative procurement cooperation, security of supply, and a strong Nordic voice, and the new NLF website details challenges shared across the five Nordic countries involved (Denmark, Finland, Iceland, Norway, and Sweden) that are to be addressed in the coming years:

  • Rising drug expenditure due to the expensive of innovative medicines and demographic change
  • An increase in supply issues
  • Limited bargaining power for small markets, and limited attractiveness of these small markets for the pharmaceutical industry.

The newly developed site has begun by sharing details of achievements to date, such as its recognition as a forum for knowledge sharing about preparations for EUHTA and EU Pharmaceutical Strategy, joint negotiations for Zynteglo, a gene therapy developed by bluebird bio, and experience sharing between Denmark, Sweden, and Norway for advanced therapy medicinal products (ATMPs).

The NLF intends to further develop in the upcoming years and achieve Nordic collaboration “developing and delivering sustainable solutions to supply medicines in the public sector”.

The new NLF website can be found here, and further information on the NLF collaboration can be found in our article here.


  1. New strategy strengthens Nordic collaboration on medicines. AMGROS. Accessed 16th February 2024.
  2. The Nordic Pharmaceutical Forum strengthens its collaboration on medicines. Remap Consulting. Accessed 16th February 2024.
  3. Nordic Pharmaceutical Forum. Accessed 16th February 2024.

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.